Collectively, this suggests a therapeutic model for the synergistic effect of APOA5 and GATA4 on TG level, which may help control an individual’s susceptibility to hyperlipidemia and other metabolic abnormalities (Fig. 6). This evidence concerns the gene GATA4 and hyperlipidemia.